Home Clinical trials For patients Uterus BGOG-EN23/TroFuse-005

BGOG-EN23/TroFuse-005

A phase 3, randomized, active-controlled, open-label, multicenter study to compare the efficacy and safety of MK-2870 monotherapy versus treatment of physician's choice in participants with endometrial cancer who have received prior platinum-based chemotherapy and immunotherapy

Open
Prior lines
1, 2, 3
Histology
Endometrioid, Mucinous Serous Clear-cell Carcinocarcoma
Phase
III

Treatment

This study consists of two different treatment options: 

  • MK-2870
  • Standard chemotherapy (Doxorubicin or Paclitaxel)

MK-2870 is administered intravenously once per fortnight. 
Doxorubicin is administered intravenously once every three weeks. 
Paclitaxel is administered intravenously on three subsequent weeks, followed by a week off.

You will be randomly allocated to one of the treatment groups. The decision on whether you receive Doxorubicin or Paclitaxel, in case you are randomized to the group receiving standard chemotherapy, is made by your treating physician.

Treatment duration

The treatment with MK-2870, Doxorubicin and Paclitaxel can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.